European Journal of Clinical Pharmacology

, Volume 32, Issue 2, pp 179–185 | Cite as

Melphalan concentration dependent plasma protein binding in healthy humans and rats

  • N. H. Greig
  • D. J. Sweeney
  • S. I. Rapoport
Originals

Summary

The binding of melphalan to plasma proteins from four healthy humans and from rats was measured by centrifugal ultrafiltration. Melphalan concentrations were determined by HPLC and by measuring 14C-melphalan activity. In whole blood, melphalan was distributed preferentially in plasma. However, a constant fraction, 37%, which was independent of the total melphalan concentration in whole blood, was present within the red blood cells. The binding of melphalan to plasma proteins from humans was less than that from rats. In both, however, the fraction bound was constant throughout the concentration range (0.1 to 9.0 µM) that is achieved during standard-dose melphalan therapy. Albumin was the primary binding protein. At concentrations equal to or in excess of 33 µM, which have been achieved during high-dose melphalan therapy, free plasma melphalan concentrations were no longer linearly related to total drug concentrations, and the plasma protein binding of melphalan in the human became concentration dependent. This occurred at concentrations of 70 µM in the rat. Scatchard analysis of the data indicated the presence of 2 groups of binding sites. Class I sites had 0.03 and 0.4 binding sites per albumin molecule in humans and rats, with respective association constants of 4.43 × 104M−1 and 1.92 × 104M−1. Class II sites had 5.18 and 2.60 binding sites per molecule, with repective association constants of 3.82 × 102M−1 and 2.01 × 102M−1.

Key words

melphalan protein binding plasma humans rats pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abramson F, Jenkins J, Ostchega Y (1982) Effects of cancer and its treatment on plasma concentrations of α1-acid glycoprotein and propanolol binding. Clin Pharmacol Ther 32: 659–663Google Scholar
  2. Ahmed A, Hsu T, El-Azhary R, Moawad H, Costanzi J (1982) Macromolecular interactions of [14C-ring] melphalan in blood. Biochem Pharmacol 31: 1615–1619Google Scholar
  3. Alberts D, Chang S, Chen S, Moon T, Evans T, Furner R, Himmelstein J (1979) Kinetics of intravenous melphalan. Clin Pharmacol Ther 26: 73–80Google Scholar
  4. Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T (1986) Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Cancer Chemother Pharmacol 16: 300–305Google Scholar
  5. Bosanquet A, Gilbey E (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18: 355–362Google Scholar
  6. Casten D, Bodenhumer M, Burcham J (1943) A study of plasma protein variation in surgical procedure. Ann Surg 117: 52–73Google Scholar
  7. Chang S, Alberts D, Farquhar D, Melnick L, Walson P, Salmon S (1978) Hydrolysis and protein binding of melphalan. J Pharm Sci 67: 682–684Google Scholar
  8. Chang S, Alberts D, Melnick L, Walson P, Salmon S (1978) High-pressure liquid chromatographic analysis of melphalan plasma. J Pharm Sci 67: 679–682Google Scholar
  9. Chirigos M, Mead J (1964) Experiments on determination of melphalan by fluoresence. Interaction with protein and various solutions. Anal Biochem 7: 259–268Google Scholar
  10. Cornbleet M, Leonard R, Smyth J (1984) High-dose agent therapy: A review of clinical experiences. Cancer Drug Delivery 1: 227–238Google Scholar
  11. Cornbleet M, McElwain T, Kumar P, Filshie J, Selby P, Carter R, Hedley D, Clark M, Millar J (1983) Treatment of advanced melanoma with high-dose melphalan and autologous bone marrow transplatation. Br J Cancer 48: 329–334Google Scholar
  12. Doumas B, Watson W, Biggs H (1971) Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 31: 87Google Scholar
  13. Dunnett C (1964) New tables for multiple comparisons with a control. Biometrics 20: 482–491Google Scholar
  14. Ehrrson H, Lonroth U (1982) Degradation of melphalan in aqueous solutions; influence of human albumin binding. J Pharm Sci 71: 826–827Google Scholar
  15. Evans T, Chang S, Alberts D, Sipes I, Brendel K (1982) In vitro degradation of L-phenylalanine mustard. Cancer Chemother Pharmacol 8: 175–178Google Scholar
  16. Fisher B, Carbone P, Economons S (1975) L-Phenylalanine mustard in the management of primary breast cancer. A report of early findings. N Engl J Med 292: 117–122Google Scholar
  17. Flora K, Smith S, Cradock J (1979) Application of a simple high-performance liquid chromatographic method for the determination of melphalan in the presence of its hydrolysis products. J Chromatogr 177: 91–97Google Scholar
  18. Furner R, Brown R, Duncan G (1977) Pharmacokinetics of the absorption, distribution and elimination of melphalan (NSC-8806) in the dog. Cancer Treat Rep 61: 1637–1646Google Scholar
  19. George R, Doth J, Gordon D (1972) Multiple myeloma-intermittent combination chemotherapy compared to continous therapy. Cancer 29: 1665–1670Google Scholar
  20. Gornall A, Bradawill C, David M (1949) Determination of serum proteins by means of biuret reagent. J Biol Chem 177: 751Google Scholar
  21. Gouyette A, Hartmann O, Pico J (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16: 184–189Google Scholar
  22. Hersh M, Ludden T, Kuhn J. Knight W (1983) Pharmacokinetics of high dose melphalan. Invest New Drugs 1: 331–334Google Scholar
  23. Herzig R, Lazarus H, Forman W, Rekate H, Lowder J, Ingalls S (1981) Central nervous system penetration of high dose intravenous L-phenylalanine mustard. Proc Am Soc Clin Oncol 22: 531Google Scholar
  24. Jackson P, Tucker J, Woods H (1982) Altered plasma binding in cancer: Role of α1-acid glycoprotein and albumin. Clin Pharmacol Ther 32: 295–302Google Scholar
  25. Jusko W, Gretch M (1976) Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metabol Rev 5: 43–140Google Scholar
  26. Knott G (1979) M-Laba mathematical modeling tool. Comput Prog Biomed 10: 271–280Google Scholar
  27. Kyle R (1975) Multiple myeloma review of 869 cases. Mayo Clin Proc 50: 29–40Google Scholar
  28. Martin B (1965) Potential effect of the plasma proteins on drug distribution. Nature 207: 274–276Google Scholar
  29. Midler G, Alling E, Morton J (1950) Effect of neoplastic and allied diseases on concentration of plasma proteins. Cancer 3: 56–65Google Scholar
  30. Miller R (1966) Simultaneous statistical inference, McGraw-Hill, New York, pp 76–81Google Scholar
  31. Piver M, Barlow J, Lee F (1975) Sequential therapy for advanced ovarian adenocarcinoma: Operation, chemotherapy, second-look laparotomy and radiation therapy. Am J Obstet Gynecol 122: 355–357Google Scholar
  32. Rosin R, Westbury G (1980) Isolated limb perfusion for malignant melanoma. Practitioner 224: 1031–1036Google Scholar
  33. Ross W (1962) Alkylating agents. Biological alkylating agents. Butterworths, London, pp 3–31, 95–193Google Scholar
  34. Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672Google Scholar
  35. Steele W, Lawrence J, Stuart J, McNeil C (1979) The protein binding of methotrexate by the serum of normal subjects. Eur J Clin Pharmacol 15: 363–366Google Scholar
  36. Steinfeld J (1960) I131 albumin degradation in patients with neoplastic diseases. Cancer 13: 974–984Google Scholar
  37. Sweeney D, Greig N, Rapoport S (1985) High-performance liquid chromatography analysis of melphalan in plasma, brain and peripheral tissue by o-phthaladehyde derivatization and fluorescence detection. J Chromatogr 339: 434–439Google Scholar
  38. Thorp J (1972) Inter and intra species differences in the binding of anionic compounds to albumin. Exerpta Medica Int Congr Ser 254: 98–109Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • N. H. Greig
    • 1
  • D. J. Sweeney
    • 1
  • S. I. Rapoport
    • 1
  1. 1.Laboratory of NeurosciencesNational Institute on Aging, National Institutes of HealthBethesdaUSA

Personalised recommendations